Entering text into the input field will update the search result below

Rexahn Pharmaceuticals, Inc. (RNN) Licenses Innovative Oncology Drug Delivery Platform

Jul. 17, 2013 4:09 PM ETOCUP
MissionIR profile picture
MissionIR's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company also has developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES.

The company reported today that it has signed an exclusive license agreement with the University of Maryland, Baltimore, for its NPDCS platform. It is a result of initial funding through a Maryland Industrial Partnership (MIPS) award. The awards are intended to foster relationships between Maryland universities and industries.

This particular technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. Rexahn's NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling component.

This approach reduces the levels of anti-cancer agents circulating in the body, which substantially lowers the risk possible adverse side effects while maximizing anti-tumor activity. Rexahn's delivery method has been shown to result in increased efficacy and reduced toxicity and beats other current delivery methods.

For additional information about Rexahn Pharmaceuticals, please visit www.rexahn.com

Please see disclaimer on the MissionIR website

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.